Journal
SCIENCE TRANSLATIONAL MEDICINE
Volume 4, Issue 163, Pages -Publisher
AMER ASSOC ADVANCEMENT SCIENCE
DOI: 10.1126/scitranslmed.3004676
Keywords
-
Categories
Funding
- M. J. Fox Foundation
- Swedish Research Council [04X-3874]
- Swedish Foundation for Strategic Research
- Ragnar Soderbergs Stiftelse
- Cure Parkinson's Trust
- Multipark program
Ask authors/readers for more resources
Glial cell line-derived neurotrophic factor (GDNF) and its close relative neurturin are currently in clinical trials for neuroprotection in patients with Parkinson disease (PD). However, in animal models of PD, GDNF fails to protect nigral dopamine (DA) neurons against alpha-synuclein-induced neurodegeneration. Using viral vector delivery of human wild-type alpha-synuclein to nigral DA neurons in rats, we show that the intracellular response to GDNF is blocked in DA neurons that overexpress alpha-synuclein. This block is accompanied by reduced expression of the transcription factor Nurr1 and its downstream target, the GDNF receptor Ret. We found that Ret expression was also reduced in nigral DA neurons in PD patients. Conditional knockout of Nurr1 in mice resulted in reduced Ret expression and blockade of the response to GDNF, whereas overexpression of Nurr1 restored signaling, providing protection of nigral DA neurons against alpha-synuclein toxicity. These results suggest that Nurr1 is a regulator of neurotrophic factor signaling and a key player in the cellular defense against alpha-synuclein toxicity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available